Assessment of liver damage in patients with COVID-19 is sub-optimal: results of a survey of medical practitioners
| Autor: | Salvador Benlloch Pérez, Moisés Diago Madrid, Carlos Alventosa Mateu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hepatitis B virus
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) SARS-CoV-2 business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Gastroenterology MEDLINE COVID-19 General Medicine Hepatitis B medicine.disease_cause Antiviral Agents Immunomodulating Agents Hepatitis B Chronic Liver Internal medicine medicine Humans In patient Liver damage business Systematic search |
| Zdroj: | Revista Española de Enfermedades Digestivas. |
| ISSN: | 1130-0108 |
| Popis: | Liver damage, defined by an increase in liver biochemical parameters, is related to a more unfavorable severity and prognosis in patients with COVID-19. These patients are also treated with immunomodulatory drugs capable of reactivating the hepatitis B virus (HBV), with indication for prophylaxis in specific situations. Due to its importance in this pathology, we wondered whether physicians should perform a systematic search for liver damage and HBV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|